...
首页> 外文期刊>Postgraduate Medical Journal >Biomarkers to guide perioperative management.
【24h】

Biomarkers to guide perioperative management.

机译:指导围手术期管理的生物标志物。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Stratifying preoperative risk and guiding perioperative therapy objectively has acquired critical importance, given robust data demonstrating that morbidity following non-cardiac surgery confers substantially increased risk of death, even beyond hospital discharge. The development of useful perioperative biomarkers depends fundamentally on both prospective morbidity data that enable the identification of higher risk patients as well as the translational understanding of pathophysiological mechanisms underlying postoperative organ dysfunction, the development of which may be specific to the perioperative environment. The emergence of cardiac insufficiency, rather than cardiac ischaemia, as the dominant factor associated with excess risk of prolonged postoperative morbidity has promoted the application of biomarkers used commonly in cardiovascular medicine. Several novel, organ specific biomarkers offer potential perioperative application. Nevertheless, common tests/biomarkers that are widely available do provide valuable, objective information that is perhaps under-utilised perioperatively. Despite significant challenges, perioperative medicine presents exciting-arguably unique-opportunities for novel biomarker development.
机译:鉴于有力的数据表明,非心脏手术后的发病率会导致甚至在出院后甚至更高的死亡风险,因此,合理地分层术前风险并指导围手术期治疗已变得至关重要。有用的围手术期生物标志物的开发从根本上取决于能够识别高危患者的前瞻性发病率数据以及对术后器官功能障碍的病理生理机制的翻译理解,其发展可能是围手术期环境所特有的。心脏功能不全而不是心脏局部缺血的出现是与术后长期发病率过高风险相关的主要因素,这促进了心血管医学中常用的生物标志物的应用。几种新颖的器官特异性生物标志物提供了潜在的围手术期应用。然而,广泛使用的通用测试/生物标记物确实提供了有价值的客观信息,这些信息可能在围手术期未被充分利用。尽管面临重大挑战,围手术期医学仍为新型生物标志物的开发提供了令人兴奋的,可以说是独特的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号